Effort of canagliflozin on metabolic syndrome parameters and biomarkers of heart, kidney and vascular diseases in patients with type 2 diabetes mellitus.
Not Applicable
- Conditions
- type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000018151
- Lead Sponsor
- Fujita Health University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with allergy for canagliflozin. 2) Patients with severe ketosis, diabetic coma, diabetic precoma, or type 1 diabetes mellitus. 3) Patients with severe renal dysfunction (eGFR<30) including the patient who needs haemodialysis or peritoneal dialysis. 4) Patients with severe infection disease or serious trauma. 5) Patient with the history of an urinary tract infection or genital infection. 6) Pregnant women and women suspected of being pregnant. 7) Women during lactation. 8) Patient who had myocardial infarction or cerebral infarction within 3 months before the informed consent. 9) Patients with insulin therapy. 10) Patients whose doctor judges to unfit for this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) HbA1c, fasting blood glucose, HOMA-R and HOMA-beta 2) Body weight, adiponectin, triglyceride, remnant-like particle cholesterol and apoB-48 3) BNP and troponin 4) Cystatin C, albuminuria, L-FABP and NGAL 5) High-sensitivity CRP 6) Symptoms and laboratory test values
- Secondary Outcome Measures
Name Time Method